Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

September 04, 2012

777 OLD SAW MILL RIVER

ROAD

FORM 4			OMB APPROVAL			
) STATES	SECURITIES AND EXCHANGE (Washington, D.C. 20549	COMMISSION	OMB Number:	3235-0287
Check this box if no longer subject to Section 16.		EMENT O	F CHANGES IN BENEFICIAL OW SECURITIES	NERSHIP OF	Expires: Estimated avburden hours	_
Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Respon	Section 17	ursuant to \$7(a) of the 30(h)	response	0.5		
1. Name and Address of Reporting Person ** GOLDBERG MURRAY A			2. Issuer Name and Ticker or Trading Symbol REGENERON	5. Relationship of I Issuer (Check	``	
(Last) ((First)	(Middle)	PHARMACEUTICALS INC [REGN] 3. Date of Earliest Transaction (Month/Day/Year)	DirectorX Officer (give to below) SVP Finance		Owner r (specify O Trea

(Street)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check
	Filed(Month/Day/Year)	Applicable Line)

X Form filed by One Reporting Person ___ Form filed by More than One Reporting

TARRYTOWN, NY 10591 — For

08/31/2012

(City)	(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Ow								y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/27/2012		$G^{(1)}$ V	600	D D	\$ 0	95,810	D	
Common Stock	08/31/2012		S(2)	503	D	\$ 144.59 (3)	95,307	D	
Common Stock	08/31/2012		S(2)	2,691	D	\$ 145.6 (4)	92,616	D	
Common Stock	08/31/2012		S(2)	1,626	D	\$ 146.37	90,990	D	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

(5) \$ Common 08/31/2012 $S^{(2)}$ 476 D 147.21 90,514 D Stock (6) Common By 401(k) Ι 5,560 Stock Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transac Code (Instr. 8	5. tionNumber of) Derivativ Securitie Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D (Month/Day, we es d	6. Date Exercisable and Expiration Date Month/Day/Year)		le and int of rlying ities . 3 and 4)	Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
			Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Relationships Reporting Owner Name / Address Other 10% Owner

Officer

Director

GOLDBERG MURRAY A 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

SVP Finance and Admin CFO Trea

Signatures

/s/**Murray A. 09/04/2012 Goldberg

**Signature of Reporting Date Person

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Gift of Common Stock to charitable organization.
- (2) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 503 shares of Company stock on August 31, 2012 at prices ranging from \$144.00 (3) to \$144.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2012 at each separate price.
- Represents volume-weighted average price of sales of 2,691 shares of Company stock on August 31, 2012 at prices ranging from \$145.03 (4) to \$145.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2012 at each separate price.
- Represents volume-weighted average price of sales of 1,626 shares of Company stock on August 31, 2012 at prices ranging from \$146.06 (5) to \$146.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2012 at each separate price.
- Represents volume-weighted average price of sales of 476 shares of Company stock on August 31, 2012 at prices ranging from \$147.10 (6) to \$147.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2012 at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.